Table 1.
Survey results regarding CMV anterior uveitis practice patterns at the biennial CKPU meeting in Bangkok, Thailand (n=68)
| Strongly disagree | Somewhat disagree | Somewhat agree | Strongly agree | |
| 1. I think that oral valganciclovir is an effective medication to treat CMV anterior uveitis | 0 (0%) | 8 (11.8%) | 36 (52.9%) | 24 (35.3%) |
| 2. I think that topical ganciclovir 2% eye drops is an effective medication to treat CMV anterior uveitis | 1 (1.5%) | 11 (16.2%) | 33 (48.5%) | 23 (33.82%) |
| 3. I think that oral valganciclovir is a safe medication to treat short term ocular inflammation related to CMV anterior uveitis | 0 (0%) | 11 (16.2%) | 36 (52.9%) | 21 (30.9%) |
| 4. I think that oral valganciclovir is a safe medication to treat long-term ocular inflammation and prevent recurrences of CMV anterior uveitis | 2 (2.9%) | 20 (29.4%) | 33 (48.5%) | 13 (19.1%) |
| 5. I think that topical ganciclovir eyedrops are a safe medication to treat short-term ocular inflammation related to CMV anterior uveitis | 1 (1.5%) | 8 (11.8%) | 28 (41.2%) | 31 (45.6%) |
| 6. I think that topical ganciclovir eyedrops are a safe medication to treat long-term ocular inflammation and prevent recurrences of CMV anterior uveitis | 1 (1.5%) | 17 (25.0%) | 31 (45.6%) | 19 (27.9%) |
| 7. I think that there is a benefit to treating CMV with long-term therapy (beyond 6 months) | 1 (1.5%) | 8 (11.8%) | 26 (38.2%) | 33 (48.5%) |
CMV, cytomegalovirus.